

B

Thomas Backenfeld : Examiner: Patrick T. Lewis

Serial No.: 10/022,845 : Group Art Unit: 1623

Filed: December 20, 2001 : Allowed: December 3, 2004

For: CYCLODEXTRIN-DROSPIRENONE INCLUSION COMPLEXES

REQUEST FOR COMPLETE NOTICE OF ALLOWANCE

MAIL STOP ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

In re Application of:

Sir:

Attached is a copy of Applicants' Information Disclosure Statement and Form 1449A/PTO filed July 2, 2003, a copy of which has not yet been returned to applicants with the examiner's initials indicating the references cited therein were considered during the prosecution of the above-identified application. It is respectfully requested that an examiner-initialed copy of Form 1449A/PTO be returned to applicants.

Respectfully submitted,

John A. Sopp (Reg. No. 33,103)

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza I 2200 Clarendon Blvd., Suite 1400

Arlington, VA 22201

Direct Dial: (703) 812-5315

Fax: (703) 243-6410

Internet address: sopp@mwzb.com

JAS:aek

Filed: January 21, 2005 k:\plovin\S\req for complete noallow

PLOVIN-0005

ATTN: PATENT PUBLICATIONS

In re Application of:

Thomas BACKENFELD et al.

Serial No.: 10/022,845

Examiner:

Patrick T. Lewis

Filed:

December 20, 2001

Group Art Unit: 1623

Title:

COMPOSITIONS OF ESTROGEN-CYCLODEXTRIN COMPLEXES

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

TIMING AND FEES

\boxtimes	Under disclos	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:						
		within three months of the filing date of a national application other than a CPA under § 1.53(d);						
		within three months of the actual filing date of the national phase of a PCT application; OR						
	\boxtimes	before the mailing of a first substantive office action (including after filing of an RCE).						
	Under periods	37 C.F.R. § 1.97(c), this information disclosure statement is filed after the specified in 37 C.F.R. § 1.97(b), but before the mailing date of:						
		a final rejection under 37 C.F.R. § 1.113;						
		termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR						
		a notice of allowance under 37 C.F.R. § 1.311; and						

	is accompanied by:						
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR				
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).				
	Under mailir	r 37 C.	F.R. § 1.97(d), this information disclosure statement is filed after the of the following actions which have not been withdrawn:				
		a fina	l action under 37 C.F.R. § 1.113;				
		termin	nation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR				
		a noti	ce of allowance under 37 C.F.R. § 1.311;				
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:				
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).				
STAT	TEMENTS	Under	237 C.F.R. 1.97(e)				
	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or						
	to the item of any inc	nunicat knowle f inform lividual	formation contained in this information disclosure statement was cited in ion from a foreign patent office in a counterpart foreign application, and dge of the undersigned attorney after making reasonable inquiry, no nation contained in this information disclosure statement was known to designated in 37 C.F.R. § 1.56(c) more than three months prior to the he information disclosure statement.				
CITE	MATER	IALS					
	ancesto	гаррис	erials listed but not attached were cited in benefit (35 U.S.C. § 120) cation Serial No, on Form 892 by the Examiner and/or Form plicant; see 37 C.F.R. § 1.98(d).				
	Copies dated _	of mate	erials listed but not attached were cited in an international search report				
\boxtimes	Copies	of the n	naterials listed are attached (except for the foregoing).				
NON-I	English	Langu	AGE REFERENCES				
	An Engi	lish-lan d indica	guage search report or equivalent paper from a foreign patent office is				

	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:								
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document 								
	A = document defining the general state of the art O = non-written disclosure								
	P = intercalated document								
	T = document cited to understand the theory or principle underlying the invention E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date								
	D = cited in the application								
	L = cited for another reason								
	& = publication of member of same patent family								
	Translation of other relevant information on foreign search report								
Отне	R INFORMATION								
langua	WO 96/02277 corresponds to U.S. Patent No. 5,798,338, already of record; 15187 corresponds to UK 2109381, cited herein; EP 398,460 contains an Englishage abstract in the form of English-language claims, also it corresponds to Canadian No. 2016780, an abstract thereof is cited here.								
<u>Paymi</u>	ENT OF FEES DUE (IF ANY):								
	A check for \$ covering the fee identified above is attached.								
	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.								
\boxtimes	The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account No. 13-3402, two copies of this paper are attached for this purpose.								
	Respectfully submitted,								
	John A. Sopp, Reg. No. 33,103 Attorney for Applicants								
	EN, WHITE, ZELANO & RANIGAN, P.C.								
Arlingt 2200 C Arlingt Telepho	con Courthouse Plaza 1, Suite 1400 Clarendon Boulevard on, Virginia 22201 one: (703) 243-6333 ile: (703) 243-6410								
Attorne	ey Docket No.: PLOVIN-5								

· · ·



JAN 2 1 2005 C

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449A/P	то		Complete if Known		
				Application Number	10/022,845	
	RMATIO			Filing Date	December 20, 2001	
STA	TEMENT I	BY APP	LICANT	First Named Inventor	Thomas BACKENFELD et al.	
				Group Art Unit	1623	
	(use as many s	heets as nec	essary)	Examiner Name	Patrick T. Lewis	
Sheet	Sheet 1 of 1		Attorney Docket Number	PLOVIN-5		

U.S. PATENT DOCUMENTS						
		U.S. Patent Document				
Examiner Initials *	Cite No.¹		ind Code ² if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	A1	4,129,564		Weichert et al.	12-12-1978	
	A2	4,877,774		Pitha et al.	10-31-1989	
_	A3	5,376,641		Ammeraal	12-27-1994	
	A4	5,885 ,9 78		Yamada et al.	03-23-1999	

				FOREIG	N PATENT DOCUMENTS			133 # Jos
Examiner Initials*	Cite No.1	Office ³	oreign Patent Docu	ument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	B1	CA	2016780	T	Wiechert et al.	07-11-2000	rigures Appear	Abstrac
	B2	ĒΡ	0398460	B1	Beier et al.	07-02-1997		
	В3	FR	2515187	A1	Stadler	10-26-1982		
	B4	UK	2109381		Gedeon et al.	06-02-1983		
	B5	wo	96/02277	A1	Backensfeld et al.	02-01-1996		

	ŝ)	NON PATENT LITERATURE DOCUMENTS	S. S.
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	ROLF KRATTENMACHER, "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen," Contraception, Vol. 2, No. 1, July 2000, pp. 29-38	Į.
	C2	P. NORMAN, "Drospirenone: Contraceptive, Hormone Replacement Therapy, Aldosterone Antagonist, Progestogen: 1, 2-Dihydrospirorenone, SH-470, ZK-30595," <i>Drugs of the Future</i> , Vol. 25, No. 12, December 2000, pp. 1247-1256	
	C3	K. UEKAMA et al., "Inclusion Complexations of Steroid Hormones With Cyclodextrins in Water and in Solid Phase," International Journal of Pharmaceutics, 10 (1982), pp. 1-15	
	C4	K. KRÁLOVÁ et al., "Interactions of β-cyclodextrin with steroid compounds in aqueous solutions," <i>Pharmazie</i> , 1989, Vol. 44, No. 9, pp. 623-625	
	C5	W.A.J.J. HERMENS, "Delivery of hormones: some new concepts," <i>Pharm. Weekbl. Sci. Ed.</i> , 1992, Vol. 14, No. 4 A, pp. 253-257	
	C6	K. UEKAMA, "Cyclodextrin Inclusion Compounds: Effects on Stability and Bio-Pharmaceutical Properties," <i>Topics in Pharmaceutical Sciences</i> , Eds. D.D. Breimer and P. Speiser, 1987, Elsevier Science Publishers (Biomedical Division), pp. 181-194	
	C 7	K. UEKAMA et al., "Cyclodextrin Drug Carrier Systems," Chem. Rev., Vol. 98, No. 5, 1 July 1998, pp. 2045-2076	
	C8	PITHA et al., "Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs," <i>International Journal of Pharmaceutics</i> , 29(1), pp. 73-82 (1986)	

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.